News
Dr Nicholas Silvestri reports that the 2025 AAN meeting highlighted significant advances in myasthenia gravis, including ...
Innovative Medicine: nipocalimab in gMG; RYBREVANT Sub-Q in NSCLC; TREMFYA Sub-Q in UC; TAR-200 NMIBC; icotrokinra in PsO and UC; RYBREVANT in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback